Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases - The evolution from myeloablative to lymphoablative transplant regimens

被引:93
作者
Burt, Richard K.
Marmont, Alberto
Oyama, Yu
Slavin, Shimon
Arnold, Renate
Hiepe, Falk
Fassas, Athanasios
Snowden, John
Schuening, Friedrich
Myint, Han
Patel, Dhavalkumar D.
Collier, David
Heslop, Helen
Krance, Robert
Statkute, Laisvyde
Verda, Larissa
Traynor, Ann
Kozak, Tomas
Hintzen, Rogier Q.
Rose, John W.
Voltarelli, Julio
Loh, Yvonne
Territo, Mary
Cohen, Bruce A.
Craig, Robert M.
Varga, John
Barr, Walter G.
机构
[1] Northwestern Univ, Div Immunotherapy, Med Ctr, Feinberg Sch Med, Chicago, IL 60011 USA
[2] San Martinos Hosp, Genoa, Italy
[3] Hadassah Univ Hosp, IL-91120 Jerusalem, Israel
[4] Univ Med Berlin, Charite, Berlin, Germany
[5] George Papanicolaou Hosp, Thessaloniki, Greece
[6] Univ Sheffield, Sheffield Teaching Hosp, Natl Hlth Serv Trust, Sheffield, S Yorkshire, England
[7] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[8] Univ Colorado, Denver Hlth Sci Ctr, Aurora, CO USA
[9] Univ N Carolina, Chapel Hill, NC USA
[10] Univ Colorado, Denver Hlth Sci Ctr, Denver, CO 80202 USA
[11] Baylor Coll Med, Houston, TX 77030 USA
[12] Texas Childrens Hosp, Houston, TX 77030 USA
[13] Univ Massachusetts, Mem Med Ctr & Med Sch, Worcester, MA 01605 USA
[14] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic
[15] Erasmus MC, Rotterdam, Netherlands
[16] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA
[17] Univ Sao Paulo, Sch Med Ribeirao Preto, Sao Paulo, Brazil
[18] Singapore Gen Hosp, Singapore 0316, Singapore
[19] Univ Calif Los Angeles, Los Angeles, CA USA
来源
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 12期
关键词
D O I
10.1002/art.22256
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
While autologous HSCT appears to induce remissions and improve quality of life in the majority of patients, it remains unclear whether either myeloablative or lymphoablative autologous HSCT can cure autoimmune disorders, and randomized controlled trials are needed to confirm the benefit and cost-effectiveness of this therapy. There are currently 2 disparate philosophical approaches to the design of these trials. One approach is to apply aggressive malignancy-specific myeloablative regimens. Although more intensive lymphoablative regimens could be designed, since cancer-specific myeloablative regimens are more intensive than currently utilized lymphoablative regimens, myeloablative regimens may result in longer duration of disease remission. The other philosophical approach is to use lymphoablative regimens that are disease specific and nonmyeloablative (i.e., do not irreversibly damage the hematopoietic stem cell compartment), maximize drugs already used to treat each disease, and avoid agents in the regimen that could cause further damage to already disease-injured organs. It appears that lymphoablative regimens are safer than myeloablative regimens, and it appears that even if relapse occurs, durable long-term remission may be achieved with conventional treatment to which the patient's disease was previously refractory. If considered on a disease-specific basis, the high disease-related mortality of SSc could justify the higher treatment-related mortality associated with a myeloablative regimen. However, since radiation is already considered a relative contraindication for SSc and radiation-induced and SSc-related microvascular compartment injuries are similar, and because TBI is associated with late myelodysplasia, leukemia, and lymphomas, some investigators have voiced concern over use of a TBI-based myeloablative regimen to treat SSc (19,59). The controversy that surrounds the competing visions of lymphoablative versus myeloablative autologous HSCT regimens for autoimmune disease has yet to be resolved. Further experience will likely indicate the superiority of one of these approaches when both safety and efficacy are considered. Since both lymphoablative and myeloablative protocols are being offered for a select group of severely ill patients with autoimmune disorders refractory to conventional therapy, subspecialists who refer patients for such therapy should be aware of the emerging body of literature that at the very least suggests that lymphoablative regimens will be associated with less morbidity and mortality. Sharing of such information is crucial if patients are to provide consent that is truly informed. © 2006, American College of Rheumatology.
引用
收藏
页码:3750 / 3760
页数:11
相关论文
共 61 条
[1]   Pulmonary complications of radiation therapy [J].
Abratt, RP ;
Onc, FR ;
Morgan, GW ;
Silvestri, G ;
Willcox, P .
CLINICS IN CHEST MEDICINE, 2004, 25 (01) :167-+
[2]   Severe fibrosis in a patient with scleroderma and previous radiotherapy - A case report and literature review [J].
Aref, I ;
Cross, P ;
Nair, B .
BRITISH JOURNAL OF RADIOLOGY, 1996, 69 (827) :1055-1056
[3]   Should we purge? [J].
Bensinger, WI .
BONE MARROW TRANSPLANTATION, 1998, 21 (02) :113-115
[4]   Phase I/II trial of autologous stem cell transplantation in systemic sclerosis:: procedure related mortality and impact on skin disease [J].
Binks, M ;
Passweg, JR ;
Furst, D ;
McSweeney, P ;
Sullivan, K ;
Besenthal, C ;
Finke, J ;
Peter, HH ;
van Laar, J ;
Breedveld, FC ;
Fibbe, VE ;
Farge, D ;
Gluckman, E ;
Locatelli, F ;
Martini, A ;
van den Hoogen, F ;
van de Putte, L ;
Schattenberg, AVN ;
Arnold, R ;
Bacon, PA ;
Emery, P ;
Espigado, I ;
Hertenstein, B ;
Hiepe, F ;
Kashyap, A ;
Kötter, I ;
Marmont, A ;
Martinez, A ;
Pascual, MJ ;
Gratwohl, A ;
Prentice, HG ;
Black, C ;
Tyndall, A .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (06) :577-584
[5]   How do CD4+CD25+ regulatory T cells control autoimmunity? [J].
Bluestone, JA ;
Tang, QZ .
CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (06) :638-642
[6]   Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease [J].
Brodsky, RA ;
Petri, M ;
Smith, BD ;
Seifter, EJ ;
Spivak, JL ;
Styler, M ;
Dang, CV ;
Brodsky, I ;
Jones, RJ .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1031-1035
[7]   Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus [J].
Burt, RK ;
Traynor, A ;
Statkute, L ;
Barr, WG ;
Rosa, R ;
Schroeder, J ;
Verda, L ;
Krosnjar, N ;
Quigley, K ;
Yaung, K ;
Villa, M ;
Takahashi, M ;
Jovanovic, B ;
Oyama, Y .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (05) :527-535
[8]   Hematopoietic stem cell transplantation for multiple sclerosis [J].
Burt, RK ;
Cohen, B ;
Rose, J ;
Petersen, F ;
Oyama, Y ;
Stefoski, D ;
Katsamakis, G ;
Carrier, E ;
Kozak, T ;
Muraro, PA ;
Martin, R ;
Hintzen, R ;
Slavin, S ;
Karussis, D ;
Haggiag, S ;
Voltarelli, JC ;
Ellison, GW ;
Jovanovic, B ;
Popat, U ;
McGuirk, J ;
Statkute, L ;
Verda, L ;
Haas, J ;
Arnold, R .
ARCHIVES OF NEUROLOGY, 2005, 62 (06) :860-864
[9]   The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis [J].
Burt, RK ;
Kallunian, K ;
Patel, D ;
Thomas, J ;
Yeager, A ;
Traynor, A ;
Heipe, F ;
Arnold, R ;
Marmont, A ;
Collier, D ;
Glatstein, E ;
Snowden, J .
BONE MARROW TRANSPLANTATION, 2004, 34 (09) :745-751
[10]   Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? [J].
Burt, RK ;
Slavin, S ;
Burns, WH ;
Marmont, AM .
BLOOD, 2002, 99 (03) :768-784